7QD Stock Chart & Stats
€3.90
-€0.10(-2.50%)
At close: 4:00 PM EDT
€3.90
-€0.10(-2.50%)
Day’s Range― - ―
52-Week Range€1.41 - €4.92
Previous CloseN/A
Volume272.00
Average Volume (3M)64.00
Market Cap
€1.97B
Enterprise Value€937.20
Total Cash (Recent Filing)€177.56M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 05, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding430,969,400
10 Day Avg. Volume27
30 Day Avg. Volume64
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.94
Price to Sales (P/S)0.63
P/FCF Ratio-17.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.51Price Target Upside15.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.03
Revenue Forecast (FY)€2.55B
Bulls Say, Bears Say
Bulls Say
Balance Sheet & Cash GenerationClover’s near-zero leverage and sizable cash balances, coupled with a recent shift to positive operating and free cash flow, give durable financial flexibility. This self-funded position supports member integration, tech and care investments, and reduces refinancing or capital-raising risk across cycles.
Scale & Membership GrowthRapid membership and revenue expansion improves unit economics through scale: fixed costs dilute, SG&A efficiency gains persist, and higher retention lets cohort-level margins improve over time. These durable scale effects support sustainable operating leverage as cohorts mature.
Clinical Platform & Home‑Care IntegrationBroad adoption of Clover Assistant and rapid growth in home-based Clover Care create structural clinical advantages. Deeper clinical touchpoints can lower utilization, strengthen provider ties, improve outcomes, and produce enduring medical-cost benefits as care-management programs scale.
Bears Say
Elevated Outpatient UtilizationPersistently higher outpatient use is a structural medical-cost headwind that can erode margin improvements from scale. If outpatient trends persist, benefit expense ratios may remain elevated, requiring sustained clinical interventions to protect long-term profitability as new cohorts age.
Part D & Risk‑Adjustment UncertaintyPolicy and program uncertainty around Part D and CMS risk models can materially affect per-member revenue and margin durability. Changes in risk-adjustment, IRA-related rules, or mix shifts can persistently alter payments and underwrite earnings volatility across multiple reporting periods.
Cybersecurity & Regulatory RiskA confirmed breach of member-facing accounts creates enduring regulatory, remediation and reputational risks. Even absent immediate financial impact, notifications, oversight, potential litigation, and trust erosion with members/brokers/providers can increase costs and pressure enrollment durability.
Clover Health Investments News
7QD FAQ
What was Clover Health Investments’s price range in the past 12 months?
Clover Health Investments lowest stock price was €1.41 and its highest was €4.92 in the past 12 months.
What is Clover Health Investments’s market cap?
Clover Health Investments’s market cap is €1.97B.
When is Clover Health Investments’s upcoming earnings report date?
Clover Health Investments’s upcoming earnings report date is Aug 05, 2026 which is in 7 days.
How were Clover Health Investments’s earnings last quarter?
Clover Health Investments released its earnings results on May 06, 2026. The company reported €0.064 earnings per share for the quarter, beating the consensus estimate of €0.061 by €0.004.
Is Clover Health Investments overvalued?
According to Wall Street analysts Clover Health Investments’s price is currently Undervalued.
Does Clover Health Investments pay dividends?
Clover Health Investments does not currently pay dividends.
What is Clover Health Investments’s EPS estimate?
Clover Health Investments’s EPS estimate is 0.03.
How many shares outstanding does Clover Health Investments have?
Clover Health Investments has 430,969,400 shares outstanding.
What happened to Clover Health Investments’s price movement after its last earnings report?
Clover Health Investments reported an EPS of €0.064 in its last earnings report, beating expectations of €0.061. Following the earnings report the stock price went up 11.009%.
Which hedge fund is a major shareholder of Clover Health Investments?
Currently, no hedge funds are holding shares in DE:7QD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clover Health Investments Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.51 (15.51% Upside)
€4.51 (15.51% Upside)
Blogger Sentiment
Bullish
DE:7QD Sentiment 75%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €504.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.53%
Trailing 12-Months
Company Description
Clover Health Investments
Clover Health Investments, Corp. is a U.S.-based firm specializing in Medicare Advantage insurance. The company leverages its proprietary software platform, the Clover Assistant, to provide both Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) health plans for individuals eligible for Medicare. In addition to its insurance operations, Clover Health also engages in non-insurance-related business ventures. The company was established in 2014 and its main office is located in Franklin, Tennessee.
7QD Company Deck
7QD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong set of operational and financial positives: rapid membership growth (~51% YoY), significant revenue growth (+62% YoY), improved gross profit (+47% YoY), GAAP profitability ($27M) and expanding clinical engagement (Clover Assistant reach and Clover Care enrollment up ~90%). Management acknowledged elevated outpatient utilization, Part D and prior-period reserve variability and one-time SG&A items, but described concrete actions (AI/data, dental cost controls, targeted remediation) and emphasized disciplined monitoring. Given the magnitude and breadth of the favorable metrics and the balance of challenges being described as manageable or being actively addressed, the overall tone is optimistic and confidence-driven while cautious on cohort maturation risks.View all DE:7QD earnings summaries7QD Stock 12 Month Forecast
Average Price Target
€4.51
▲(15.51% Upside)